Travere Therapeutics (TVTX) Interest & Investment Income (2013 - 2026)
Travere Therapeutics (TVTX) posted Interest & Investment Income of $2.6 million for Q1 2026, little changed on a QoQ basis from $2.6 million in Q4 2025, and down 31.91% year-over-year from $3.8 million in Q1 2025.
Travere Therapeutics (TVTX) Interest & Investment Income (2013 - 2026) Analysis & Trends
Travere Therapeutics' Interest & Investment Income history runs 8 years deep, the most recent figure standing at $2.6 million for Q1 2026.
- Quarterly Interest & Investment Income fell 31.91% year-over-year to $2.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $11.5 million (down 26.12% YoY) and the FY2025 annual result came in at $12.7 million, down 28.6% from the prior year.
- Interest & Investment Income was $2.6 million for Q1 2026 at Travere Therapeutics, roughly flat from $2.6 million in the prior quarter.
- Across five years, Interest & Investment Income topped out at $7.2 million in Q4 2023 and bottomed at $278000.0 in Q1 2022.
- A 5-year average of $3.6 million and a median of $3.6 million in 2024 frame the typical range for Interest & Investment Income.
- Annual changes were most pronounced in 2022 — Interest & Investment Income surged 1219.92% — and 2024, when it plunged 46.94%.
- Travere Therapeutics' Interest & Investment Income stood at $3.1 million in 2022, then surged by 129.6% to $7.2 million in 2023, then slumped by 46.94% to $3.8 million in 2024, then plunged by 31.7% to $2.6 million in 2025, then dropped by 0.31% to $2.6 million in 2026.
- Business Quant data shows TVTX's Interest & Investment Income at $2.6 million in Q1 2026, $2.6 million in Q4 2025, and $3.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int & Inv Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 27.66 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 114.80 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -65.80 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 48.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 19.51 Mn |
| 10 | Travere Therapeutics | 5.24 Bn | 5.24 Bn | 125.25 Mn | 2.58 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 2.58 Mn |
| Dec 31, 2025 | 2.59 Mn |
| Sep 30, 2025 | 3.05 Mn |
| Jun 30, 2025 | 3.29 Mn |
| Mar 31, 2025 | 3.80 Mn |
| Dec 31, 2024 | 3.80 Mn |
| Sep 30, 2024 | 3.57 Mn |
| Jun 30, 2024 | 4.42 Mn |
| Mar 31, 2024 | 6.03 Mn |
| Dec 31, 2023 | 7.15 Mn |
| Sep 30, 2023 | 5.84 Mn |
| Jun 30, 2023 | 5.13 Mn |
| Mar 31, 2023 | 3.65 Mn |
| Dec 31, 2022 | 3.12 Mn |
| Sep 30, 2022 | 2.10 Mn |
| Jun 30, 2022 | 782,000.00 |
| Mar 31, 2022 | 278,000.00 |
| Dec 31, 2021 | 236,000.00 |
| Sep 30, 2021 | 360,000.00 |
| Jun 30, 2021 | 988,000.00 |